| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Microvascular Research Laboratories, Department of Physiology, University of Bristol, Preclinical Veterinary School, Bristol BS2 8EJ; and 2 Department of Pathology, 3 Academic and 4 Children's Renal Unit, University of Bristol, and 5 Bristol Urological Institute, Southmead Hospital, Westbury on Trym, Bristol BS10 5NB, United Kingdom
Vascular endothelial growth factor (VEGF) is expressed by renal glomerular epithelial cells (podocytes) and is thought to be protective against nephrotoxic agents. VEGF has been shown to be an autocrine survival factor in neuropilin-1-positive, VEGF receptor-negative breast carcinoma cells. Normal human podocytes are also known to express neuropilin-1, VEGF, and are VEGF-R2 negative. Here, we investigated whether a similar VEGF autocrine loop may exist in podocytes. Podocyte cytosolic calcium concentration ([Ca2+]i) was analyzed in primary cultured and conditionally immortalized podocytes using ratiometric fluorescence measurement. Cytotoxicity was determined by lactate dehydrogenase assay, proliferation by [3H]-thymidine incorporation, and cell counts by hemocytometric assay. VEGF decreased [Ca2+]i in primary podocytes (from 179 ± 36 to 121 ± 25 nM, P < 0.05) and conditionally immortalized podocytes (from 95 ± 10 to 66 ± 8 nM, P < 0.02) in the absence of extracellular calcium. The type III receptor tyrosine-kinase inhibitor PTK787/ZK222584 abolished this reduction. VEGF increased podocyte [3H]-thymidine incorporation (3,349 ± 283 cpm, control 2,364 ± 301 cpm, P < 0.05) and cell number (4.5 ± 0.7 × 104/ml, control 2.6 ± 0.5 × 104/ml, P < 0.05) and decreased cytotoxicity (5.9 ± 0.7%, control 12 ± 3%, P < 0.05), whereas a monoclonal antibody to VEGF increased cytotoxicity. Electron microscopy of normal human glomeruli demonstrated that the glomerular VEGF is mostly podocyte cell membrane associated. These results indicate that one of the functions of VEGF secreted from podocytes may be to act as an autocrine factor on calcium homeostasis and cell survival.
intracellular calcium; apoptosis; glomerulus; cell survival; immunogold
This article has been cited by other articles:
|
|
 |
|
  J.-W. Gu, R. D. Manning Jr., E. Young, M. Shparago, B. Sartin, and A. P. Bailey Vascular endothelial growth factor receptor inhibitor enhances dietary salt-induced hypertension in Sprague-Dawley rats Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2009; 297(1): R142 - R148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. N. Korgaonkar, X. Feng, M. D. Ross, T.-c. Lu, V. D'Agati, R. Iyengar, P. E. Klotman, and J. C. He HIV-1 Upregulates VEGF in Podocytes J. Am. Soc. Nephrol., May 1, 2008; 19(5): 877 - 883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Eremina, J. A. Jefferson, J. Kowalewska, H. Hochster, M. Haas, J. Weisstuch, C. Richardson, J. B. Kopp, M. G. Kabir, P. H. Backx, et al. VEGF Inhibition and Renal Thrombotic Microangiopathy N. Engl. J. Med., March 13, 2008; 358(11): 1129 - 1136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Quaggin and J. A. Kreidberg Development of the renal glomerulus: good neighbors and good fences Development, February 15, 2008; 135(4): 609 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Liu, M. Morimoto, S. Kitajima, T. Koike, Y. Yu, H. Shiiki, M. Nagata, T. Watanabe, and J. Fan Increased Expression of Vascular Endothelial Growth Factor in Kidney Leads to Progressive Impairment of Glomerular Functions J. Am. Soc. Nephrol., July 1, 2007; 18(7): 2094 - 2104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Wilkinson, T. Gilbert, G. Kinna, L.-A. Ruta, D. Pennisi, M. Kett, and M. H. Little Crim1KST264/KST264 Mice Implicate Crim1 in the Regulation of Vascular Endothelial Growth Factor-A Activity during Glomerular Vascular Development J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1697 - 1708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Burt, M. S. Forbes, B. A. Thornhill, S. C. Kiley, and R. L. Chevalier Renal vascular endothelial growth factor in neonatal obstructive nephropathy. I. Endogenous VEGF Am J Physiol Renal Physiol, January 1, 2007; 292(1): F158 - F167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Albaqumi, T. J. Soos, L. Barisoni, and P. J. Nelson Collapsing Glomerulopathy J. Am. Soc. Nephrol., October 1, 2006; 17(10): 2854 - 2863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Guan, G. Villegas, J. Teichman, P. Mundel, and A. Tufro Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP Am J Physiol Renal Physiol, August 1, 2006; 291(2): F422 - F428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B Zhao, A Ma, J Cai, and M Boulton VEGF-A regulates the expression of VEGF-C in human retinal pigment epithelial cells Br. J. Ophthalmol., August 1, 2006; 90(8): 1052 - 1059. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A R L Medford and A B Millar Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): paradox or paradigm? Thorax, July 1, 2006; 61(7): 621 - 626. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Foster, S. C. Satchell, J. Seckley, M. S. Emmett, K. Joory, C. Y. Xing, M. A. Saleem, P. W. Mathieson, D. O. Bates, and S. J. Harper VEGF-C promotes survival in podocytes Am J Physiol Renal Physiol, July 1, 2006; 291(1): F196 - F207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Eremina, S. Cui, H. Gerber, N. Ferrara, J. Haigh, A. Nagy, M. Ema, J. Rossant, S. Jothy, J. H. Miner, et al. Vascular Endothelial Growth Factor A Signaling in the Podocyte-Endothelial Compartment Is Required for Mesangial Cell Migration and Survival J. Am. Soc. Nephrol., March 1, 2006; 17(3): 724 - 735. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. J. Salmon, C. R. Neal, D. O. Bates, and S. J. Harper Vascular endothelial growth factor increases the ultrafiltration coefficient in isolated intact Wistar rat glomeruli J. Physiol., January 1, 2006; 570(1): 141 - 156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Wolf, S. Chen, and F. N. Ziyadeh From the Periphery of the Glomerular Capillary Wall Toward the Center of Disease: Podocyte Injury Comes of Age in Diabetic Nephropathy Diabetes, June 1, 2005; 54(6): 1626 - 1634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nangaku, S. J. Shankland, and W. G. Couser Cellular Response to Injury in Membranous Nephropathy J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1195 - 1204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A R L Medford, L J Keen, J L Bidwell, and A B Millar Vascular endothelial growth factor gene polymorphism and acute respiratory distress syndrome Thorax, March 1, 2005; 60(3): 244 - 248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J.M. Coward, R. R. Foster, D. Patton, L. Ni, R. Lennon, D. O. Bates, S. J. Harper, P. W. Mathieson, and M. A. Saleem Nephrotic Plasma Alters Slit Diaphragm-Dependent Signaling and Translocates Nephrin, Podocin, and CD2 Associated Protein in Cultured Human Podocytes J. Am. Soc. Nephrol., March 1, 2005; 16(3): 629 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Foster, M. A. Saleem, P. W. Mathieson, D. O. Bates, and S. J. Harper Vascular endothelial growth factor and nephrin interact and reduce apoptosis in human podocytes Am J Physiol Renal Physiol, January 1, 2005; 288(1): F48 - F57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Woolard, W.-Y. Wang, H. S. Bevan, Y. Qiu, L. Morbidelli, R. O. Pritchard-Jones, T.-G. Cui, M. Sugiono, E. Waine, R. Perrin, et al. VEGF165b, an Inhibitory Vascular Endothelial Growth Factor Splice Variant: Mechanism of Action, In vivo Effect On Angiogenesis and Endogenous Protein Expression Cancer Res., November 1, 2004; 64(21): 7822 - 7835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chen, Y. Kasama, J. S. Lee, B. Jim, M. Marin, and F. N. Ziyadeh Podocyte-Derived Vascular Endothelial Growth Factor Mediates the Stimulation of {alpha}3(IV) Collagen Production by Transforming Growth Factor-{beta}1 in Mouse Podocytes Diabetes, November 1, 2004; 53(11): 2939 - 2949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Bocci, S. Man, S. K. Green, G. Francia, J. M. L. Ebos, J. M. du Manoir, A. Weinerman, U. Emmenegger, L. Ma, P. Thorpe, et al. Increased Plasma Vascular Endothelial Growth Factor (VEGF) as a Surrogate Marker for Optimal Therapeutic Dosing of VEGF Receptor-2 Monoclonal Antibodies Cancer Res., September 15, 2004; 64(18): 6616 - 6625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. K. Lee, N. D. Bone, A. K. Strege, T. D. Shanafelt, D. F. Jelinek, and N. E. Kay VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia Blood, August 1, 2004; 104(3): 788 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Chung, S. Yoon, K. Datta, R. E. Bachelder, and A. M. Mercurio Hypoxia-Induced Vascular Endothelial Growth Factor Transcription and Protection from Apoptosis Are Dependent on {alpha}6{beta}1 Integrin in Breast Carcinoma Cells Cancer Res., July 15, 2004; 64(14): 4711 - 4716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Zelzer, R. Mamluk, N. Ferrara, R. S. Johnson, E. Schipani, and B. R. Olsen VEGFA is necessary for chondrocyte survival during bone development Development, May 1, 2004; 131(9): 2161 - 2171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-G. Cui, R. R. Foster, M. Saleem, P. W. Mathieson, D. A. Gillatt, D. O. Bates, and S. J. Harper Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF165b) mRNA and protein Am J Physiol Renal Physiol, April 1, 2004; 286(4): F767 - F773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. O. Bates and R. O. P. Jones The Role of Vascular Endothelial Growth Factor in Wound Healing International Journal of Lower Extremity Wounds, June 1, 2003; 2(2): 107 - 120. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
